Final Report

Inno-HTA final report

Journal articles

Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review
by Susanne Hartz (Friedrich-Schiller-University of Jena) and Jürgen John (Helmholtz Zentrum München, Institute of Health Economics and Healthcare Management)

International Journal of Technology Assessment in Health Care, 24:4 (2008), 465–472.
doi:10.1017/S0266462308080616

Public health policy decisions on medical innovations: What role can early economic evaluation play?
by Susanne Hartz (Friedrich-Schiller-University of Jena) and Jürgen John (Helmholtz Zentrum München, Institute of Health Economics and Healthcare Management)

Health Policy, Volume 89, Issue 2, Pages 184-192 (February 2009).
doi:10.1016/j.healthpol.2008.05.011

Innovation im Gesundheitswesen: Die Rolle von HTA bei der Einführung neuer Technologien (Innovation in health care: The role of HTA in the introduction of new technologies)
by Bernhard Bührlen (Fraunhofer ISI)

Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, corrected proof (2010).
doi:10.1016/j.zefq.2010.10.012

Presentations

Poster presentation of Inno-HTA is invited to the

European Health Forum Gastein

'Financial Crisis and Health Policy'

30th September - 3rd October 2009, within the Forum on HTA

Parallel Panel Session organised by Inno-HTA

Supporting healthcare innovation management by comprehensive early assessment

at HTAi 2009: Globalisation and Health Technology Assessment, Singapore

Abstract of the session

Presentations:

Introduction
B. Buehrlen

Requirements for healthcare innovations from the public health perspective
Finn Børlum Kristensen

Approaches to identify, assess, and manage healthcare innovations
Iñaki Gutiérrez Ibarluzea

Innovation management in the pharmaceutical sector
Clare McGrath

Find all presentations of HTAi2009 here.

Conference HTAi 2008:
Health Technology Assessment in Context, Montréal, Canada

including presentation by Inno-HTA

Bernhard Buehrlen and the Inno-HTA consortium:
Indicators for the assessment of healthcare innovations (PDF. 54 KB).
Abstract Number: 425
Theme:  HTA in decision-making 2
Viewing Date: July, 8th 2008

Conference website

Conference HTAi 2007:
HTA FOR EVIDENCE-BASED PUBLIC HEALTH

Posters presented
Bernhard Buehrlen and the Inno-HTA consortium: HTA-Methodology for Innovative Healthcare Technologies (Inno-HTA) (PDF, 157 KB) and

Susanne Hartz & Jürgen John: Contributions of economic evaluation to early phases of product development: A methodological and empirical review (PDF, 48KB)

Presentations at the public Inno-HTA Dissemination Workshop

"Inno-HTA: Adding value to comprehensive early assessment of health care innovations from a public and private perspective"

4th of December 2008, Hotel Admiral, Copenhagen

Invitation and programme

Presentations:

Workshop opening
Finn Børlum Kristensen. National Board of Health, Project leader European Network for HTA – EunetHTA, Adjunct Professor, University of Southern Denmark

Constructive assessment of emerging technologies: bridging the gap between innovation and regulation
Arie Rip. Professor of Philosophy of Science and Technology in the School of Management and Governance of the University of Twente, The Netherlands

Results of Inno-HTA
Bernhard Buehrlen, Coordinator Inno-HTA project, Fraunhofer Institute

EUnetHTA Common Core HTA and Added value of Inno-HTA in relation to ‘classic’ HTA
Kristian Lampe, Senior Medical Officer, FinOHTA, project leader of EunetHTA WP4 on developing a core model for HTA

Added value of Inno-HTA for producers/manufacturers’ R&D decision-making
Richard Bergström, Vice-chair of EFPIA’s (The European Federation of Pharmaceutical Industries and Assocations) HTA Working Group, Director-General of LIF, The Swedish Association of the Pharmaceutical Industry.

Added value of Inno-HTA for consumers/patients
Cees Smit, The Dutch Genetic Alliance (VSOP), Honorary member of Epposi, The European Platform for Patients' Organisations, Science and Industry.

Added value of Inno-HTA to support national and European R&D policy
Fabian Waechter, former at Austrian Agency for Health and Food Safety (AGES)

Startpage